Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices

Pulmonary Pharmacology and Therapeutics

Volumn 10, Issue 4, 1997, Pages 211-214

  Lipworth, B J ^a   Clark, D J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Bioavailability; Breath activated; Chlorofluorocarbon; Deposition; Dry powder inhaler; Pressurized metered dose aerosol; Salbutamol

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL;

ADULT; AEROSOL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRY POWDER; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0031215161     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1997.0093     Document Type: Article

References (15)

1. 1. Crompton G K. Problems patients having used pressurised aerosol inhalers. Eur J Respir Dis 1982; 63 (Suppl 119): 101-104.
2. 2. Pedersen S. Choice of inhalation therapy in asthmatics. Eur Respir Rev 1994; 4: 86-89.
3. 3. Siafakas N M, Bouros D. Choice of inhalation therapy in adults. Eur Respir Rev 1994; 4: 78-81.
4. 4. Newman S P, Weisz AWB, Talaee N, Clark S W. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46: 712-716.
5. 5. Partridge MR. Metered-dose inhalers and CFCs: What respiratory physicians need to know. Respir Med 1994; 88: 645-647.
6. 6. Lipworth B J. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996; 42: 697-705.
7. 7. Chrystyn H, Corlett S A, Silkstone V. Lung bioavailability of generic and innovator salbutamol MDIs. Thorax 1996; 51: 658.
8. 8. Lipworth B J, Clark R A, Dhillon D P, Moreland T A, Struthers A D, Clark G A, McDevitt D G. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Eur J Clin Pharmacol 1989; 37: 567-571.
9. 2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose inhaler and modified actuator devices. Br J Clin Pharmacol 1993; 36: 445-450.
10. 10. Clark D J, Lipworth B J. Lung bioavailability of chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996; 41: 247-249.
11. 11. Clark D J, Gordon-Smith J, McPhate G, Clark G, Lipworth B J. Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax 1996; 51: 325-326.
12. 12. Clark D J, Lipworth B J. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax 1996; 51: 981-984.
13. 13. Lipworth B J, McDevitt D G. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol 1989; 36: 239-245.
14. 14. Newnham D M, Lipworth B J. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (Ventstream). Thorax 1994; 49: 762-766.
15. 15. Mackie A E, Falcoz C, McDowell J E, Moss J, Ventresca G P, Bye A. Pharmacokinetics of fluticasone propionate inhaled from the diskhaler and the diskus powder devices in healthy subjects. Br J Clin Pharmacol 1997; 43: 540P-541P.